Bridgebio Pharma, Inc. (BBIO)

Trade BBIO now with
6/22/2022 8:17:18 AM BridgeBio Pharma Announces Early Positive Data For BBP-812 For Canavan Disease
5/20/2022 7:59:50 AM Phoenix Tissue Repair Says Positive Results From Phase 2 Trial Of PTR-01 For Recessive Dystrophic Epidermolysis Bullosa
4/3/2022 2:02:00 PM BridgeBio Pharma Presents Updated Results From Phase 2 Open-label Extension Study Of Acoramidis In ATTR-CM
3/14/2022 7:34:05 AM BridgeBio Pharma Announces Positive Phase 2 Data Of BBP-418 For Limb-girdle Muscular Dystrophy Type 2i
3/8/2022 7:37:36 AM BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For NULIBRY
12/27/2021 7:14:49 AM BridgeBio Pharma Says ATTRibute-CM Did Not Meet Primary Endpoint At Month 12
12/10/2021 7:38:03 AM BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/18/2021 7:41:07 AM BridgeBio Pharma Executes Definitive Credit Facility Deal With A Syndicate Of Lenders For Up To $750.0 Mln In Financing
10/29/2021 7:32:44 AM BridgeBio Pharma Collaborates With Columbia University To Develop Therapies For Genetic Diseases And Cancers
10/7/2021 9:20:44 AM BridgeBio Announces Publication Of Data For Best-in-Class SHP2 Inhibitor Designed For Treatment Of Resistant Cancer
9/15/2021 7:33:24 AM BridgeBio Receives FDA Fast Track Designation For Therapy For Treatment Of Limb-girdle Muscular Dystrophy Type 2i
8/5/2021 7:49:57 AM BridgeBio Pharma Q2 Loss/shr Narrows $0.66 From $1.03 Last Year
7/8/2021 7:33:14 AM BridgeBio Pharma Announces Collaborations With Three Academic Research Institutions